C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 27, Issue 1, 2010, Pages 49-56

  Sweiss, N J ^a   Barnathan, E S ^b   Lo, K ^b   Judson, M A ^c   Baughman, R ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTOCOR INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

3 minute walk distance; C reactive protein; Forced vital capacity; Infliximab; Saint George's respiratory questionnaire; Sarcoidosis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; DYSPNEA; FEMALE; FORCED VITAL CAPACITY; HUMAN; LUNG SARCOIDOSIS; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; WALKING;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAL CAPACITY; WALKING;

EID: 77957574847     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol 1993; 91 (4): 939-49.
2. Sweiss NJ, Curran J, Baughman RP. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol 2007; 25 (3): 341-6.
3. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1): 1885-9.
4. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100 (11): 2053-9. (Pubitemid 44514944)
5. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127 (3): 1064-71.
6. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7): 795-802.
7. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (6): 1189-96.
8. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63 (6): 665-70.
9. Gratacós J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007; 66 (4): 493-7. (Pubitemid 46580470)
10. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54 (3): 702-10.
11. Pietinalho A, Ohmichi M, Hiraga Y, Löfroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13 (2): 159-66.
12. Standardized questionaries on respiratory symptoms. BMJ 1960; 2 (5213): 1665.
13. Jones PW, Quirk FH, Baveystock CM, Litdejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145 (6): 1321-7.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166 (1): 111-7.
15. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132 (8): 919-23.
16. Borg G. Borg's perceived exertion and pain scales. Champaign, IL: Human Kinetics; 1998.
17. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
18. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002; 1 (3): 264-75.
19. Foss NT, de Oliveira EB, Silva CL. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int J Lepr Other Mycobact Dis. 1993; 61 (2): 218-26.
20. Müller-Quemheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145 (1): 187-92.
21. Bachwich PR, Lynch JP, 3rd, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986; 125 (3): 421-5.
22. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203 (2): 359-70.
23. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115 (1): 36-42.
24. Zheng L, Teschler H, Guzman J, Hübner K, Striz I, Costabel U. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995; 152 (3): 1061-6.
25. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156 (5): 1586-92. (Pubitemid 27505529)
26. Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004; 63 (1): 84-7.
27. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67 (4): 511-7.
28. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37 (7): 818-24.
29. Haider DG, Leuchten N, Schaller G, et al. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006; 146 (3): 533-9. (Pubitemid 44722173)
30. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005; 52 (7): 2146-58.
31. Pabst S, Baumgarten G, Stremmel A, et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006; 143 (3): 420-6.
32. Chou CY, Kuo HL, Lin HH, Liu JS, Liu YL, Huang CC. C-reactive protein predicts ischaemic stroke in haemodialysis patients. Int J Clin Pract 2009; 63 (2): 243-8.